OUR FACILITIES
WILL REMAIN OPEN & OPERATIONAL DURING THE COVID-19 PANDEMIC

517
Active Clinical Trials
4
Commercial Products
350,000+
Shipments
100+
Countries

Upcoming Events View All

JAN25

IPPE Marketplace

Date: January 25-29, 2021

Location: Virtual Event

JAN26

Advanced Therapies Connect

Date: January 26-27, 2021

Location: Virtual Event

The Latest From Our Blog View All

Forbes Honors Cryoport, Inc. on 2021 ‘100 Best Small Companies’ List

2020 was an incredible year of growth for Cryoport, Inc. The acquisitions of CRYOPDP and MVE Biological Solutions dramatically increased our global network and capabilities, and we achieved a new record of supporting over 500 clinical trials worldwide. During a calamitous year in which the COVID-19 pandemic disrupted supply chains all over the planet, we provided continuous steadfast service to our customers, including our support for 26 COVID-19 vaccine trials.

Now That A Brexit Deal Has Been Negotiated, Here Is What Cryoport Clients Can Expect

Background information

On January 31, 2020, the United Kingdom (UK) officially withdrew from the European Union (EU).   An eleven-month transition period was enacted to negotiate trade terms between the UK and the EU, and this transition period expired on December 31, 2020.

Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC

Exciting News! Cryoport, Inc., our parent company, has expanded its family of companies in continuing to support temperature controlled supply chain solutions for the life sciences industry. Learn More